Multiple Myeloma Clinical Trials in Irvine, California

14 studies are recruiting for multiple myeloma in Irvine, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

   The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).

   Stage

   Phase 3

   Ages

   18 and older

   Site

   City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California

   Locations

   270 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT05552222 on ClinicalTrials.gov

2. A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

   The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California

   Locations

   157 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07258511 on ClinicalTrials.gov

3. A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

   The purpose of this study is to find out whether giving a single dose of tocilizumab before treatment with ramantamig can help prevent or reduce the severity of cytokine release syndrome (CRS) within 28 days from ramantamig, compared to participants who receive placebo. CRS is an acute inflammatory…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California

   Locations

   60 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07589634 on ClinicalTrials.gov

4. AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

   This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics and efficacy of AZD0305 as monotherapy and in combination with other anticancer agents in participants with MM.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Irvine, California

   Locations

   46 in total

   Run by

   AstraZeneca

   See if you can join NCT06106945 on ClinicalTrials.gov

5. Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study

   This clinical trial compares the effectiveness of geriatric assessment (GA) guided interventions to accelerate functional recovery after chimeric antigen receptor T-cell (CAR-T) therapy compared to standard of care (SOC) in patients 60 years and older with B-cell non-Hodgkin lymphoma (NHL) or multi…

   Stage

   Phase 2

   Ages

   60 and older

   Site

   City of Hope at Irvine Lennar, Irvine, California

   Locations

   4 in total

   Run by

   City of Hope Medical Center

   See if you can join NCT06052826 on ClinicalTrials.gov

6. A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

   This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab plus daratumumab and dexamethasone (Dd) which will be administered to pa…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope - Lennar Foundation Cancer Center, Irvine, California

   Locations

   34 in total

   Run by

   Genentech, Inc.

   See if you can join NCT04910568 on ClinicalTrials.gov

7. A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

   Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety, tolerability, and how ABBV-438 moves through the body, in adult participants with relapsed/refractory (R/R) MM. Adverse events, to…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope - Orange County Lennar Foundation Cancer Center /ID# 279067, Irvine, California

   Locations

   14 in total

   Run by

   AbbVie

   See if you can join NCT07409246 on ClinicalTrials.gov

8. A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

   Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapse…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope - Orange County Lennar Foundation Cancer Center /ID# 277911, Irvine, California

   Locations

   36 in total

   Run by

   AbbVie

   See if you can join NCT06892522 on ClinicalTrials.gov

9. Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

   The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple myeloma (MM) who have received one to three prior lines of therapy and have been exposed to an anti-C…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   City of Hope - Lennar Foundation Cancer Center, Irvine, California

   Locations

   93 in total

   Run by

   Hoffmann-La Roche

   See if you can join NCT07555938 on ClinicalTrials.gov

10. A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

    This is a phase 1/2 multicenter, open-label, first-in-human study of IBI3003. It includes a phase 1 dose escalation and expansion section to identify maximum tolerated dose(MTD)/recommended Phase 2 Dose(RP2D) of IBI3003, plans to enroll 54~360 subjects, and a phase 2 stage to explore efficacy, safe…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope - Lennar, Irvine, California

    Locations

    6 in total

    Run by

    Fortvita Biologics (USA)Inc.

    See if you can join NCT07336472 on ClinicalTrials.gov

11. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

    The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    UC Irvine Health Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California

    Locations

    173 in total

    Run by

    Janssen Research & Development, LLC

    See if you can join NCT07518186 on ClinicalTrials.gov

12. MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

    The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years of age or older and have MM. * Have received treatments befo…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Hoag Health Center Irvine, Irvine, California

    Locations

    270 in total

    Run by

    Pfizer

    See if you can join NCT06152575 on ClinicalTrials.gov

13. Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

    This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.

    Stage

    Phase 4

    Ages

    18 and older

    Site

    UCI Health - Irvine Infusion Pharmacy ACC, Irvine, California

    Locations

    33 in total

    Run by

    Pfizer

    See if you can join NCT06057402 on ClinicalTrials.gov

14. A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients

    This study assesses the impact of cannabis (also commonly called marijuana, weed, or THC) use on quality of life among patients with multiple myeloma who are receiving chemotherapy. It also evaluates the potential benefits and harms of cannabis use.

    Stage

    Not phased

    Ages

    18 and older

    Site

    City of Hope at Irvine Lennar, Irvine, California

    Locations

    11 in total

    Run by

    City of Hope Medical Center

    See if you can join NCT07225738 on ClinicalTrials.gov